A Real-World Study of Safety, Immunogenicity and Efficacy of Bevacizumab in Patients With Solid Malignancies: A Phase IV, Post-Marketing Study in India

OBJECTIVE: The aim of this study was to evaluate the post-marketing safety, tolerability, immunogenicity and efficacy of Bevacizumab (manufactured by Hetero Biopharma) in a broader population of patients with solid tumors. PATIENTS AND METHODS: This phase IV, prospective, multi-centric clinical stud...

Descripción completa

Detalles Bibliográficos
Autores principales: Sinha, Shubhadeep D, Biswas, Ghanashyam, Bheemareddy, Bala Reddy, Chary, Sreenivasa, Thakur, Pankaj, Jain, Minish, Maksud, Tanveer, Pawar, Suraj, Chatterjee, Koushik, Voonna, Murali Krishna, Goel, Anil, Puligundla, Krishna Chaitanya, Lakshmaiah, Kuntegowdanahalli Chinnagiriyappa, Talluri, Leela, Vattipalli, Ramya, Kakkunnath, Sheejith
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10259146/
https://www.ncbi.nlm.nih.gov/pubmed/37313371
http://dx.doi.org/10.1177/11769351231177277

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10259146/
https://www.ncbi.nlm.nih.gov/pubmed/37313371
http://dx.doi.org/10.1177/11769351231177277

Ejemplares similares